Hoisex Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hoisex Gomez has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Angélica Mondragón
Division of Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
1 shared publication Carmen Soto
Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic
1 shared publicationCésar Rodriguez
Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic
1 shared publication- David R. Doody
Division of Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
1 shared publication - Diego Guillen
MSF Foundation, Paris, France
1 shared publication Emma Brofsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD
1 shared publication
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (11)
Human Papillomavirus Testing Compared With Cytology for Cervical Cancer Screening Among Women Living With HIV in the Dominican Republic
Purpose: Women living with HIV (WWH) face elevated cervical cancer risk, yet evidence supporting primary human papillomavirus (HPV) testing in low-resource settings remains limited. We compared HPV testing with cytology for detection of cervical precancer among WWH in the Dominican Republic to inform national screening strategies. Methods: In this cross-sectional analysis from US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network Trial 302 (Estudio Oportunidad, ClinicalTrials.gov identifier: NCT05556772 ), 575 WWH contributed provider- and self-collected samples for cytology and HPV hierarchical testing. Women with positive results on cytology, provider-collected HPV testing, or self-collected HPV testing were referred for colposcopy and biopsy. Screening test characteristics were evaluated using centrally adjudicated histologic end points. Results: Women with positive results on any screening test had higher HIV viral loads, lower CD4 counts, and were younger than women with screen-negative results. Sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN3+) by cytology (66.7% [95% CI, 49.2 to 80.5]) was lower than sensitivity of provider-collected results with either 13 high-risk HPV (hrHPV) genotypes (93.9 [95% CI, 78.7 to 98.5]) or 8 hrHPV genotypes (84.8% [95% CI, 68.3 to 98.6]). Self-collected samples had the highest sensitivity (97.0%, 95% CI, 81.3 to 99.6). Cytology missed 33.3% of CIN3+, hrHPV testing of provider-collected samples missed 6.1%-15.2% of CIN3+, and hrHPV testing of self-collected samples missed 3.0% of CIN3+. Conclusion: Among WWH in the Dominican Republic, HPV testing, whether provider- or self-collected, outperformed cytology for detection of CIN3+. Both 13- and 8-genotype hrHPV panels demonstrated high sensitivity but low specificity, resulting in high referral rates to colposcopy. These findings support transitioning to primary HPV-based screening for WWH in the Dominican Republic to increase accuracy in detecting precancer and reduce the cervical cancer burden among WWH.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (11)
Human Papillomavirus Testing Compared With Cytology for Cervical Cancer Screening Among Women Living With HIV in the Dominican Republic
Purpose: Women living with HIV (WWH) face elevated cervical cancer risk, yet evidence supporting primary human papillomavirus (HPV) testing in low-resource settings remains limited. We compared HPV testing with cytology for detection of cervical precancer among WWH in the Dominican Republic to inform national screening strategies. Methods: In this cross-sectional analysis from US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network Trial 302 (Estudio Oportunidad, ClinicalTrials.gov identifier: NCT05556772 ), 575 WWH contributed provider- and self-collected samples for cytology and HPV hierarchical testing. Women with positive results on cytology, provider-collected HPV testing, or self-collected HPV testing were referred for colposcopy and biopsy. Screening test characteristics were evaluated using centrally adjudicated histologic end points. Results: Women with positive results on any screening test had higher HIV viral loads, lower CD4 counts, and were younger than women with screen-negative results. Sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN3+) by cytology (66.7% [95% CI, 49.2 to 80.5]) was lower than sensitivity of provider-collected results with either 13 high-risk HPV (hrHPV) genotypes (93.9 [95% CI, 78.7 to 98.5]) or 8 hrHPV genotypes (84.8% [95% CI, 68.3 to 98.6]). Self-collected samples had the highest sensitivity (97.0%, 95% CI, 81.3 to 99.6). Cytology missed 33.3% of CIN3+, hrHPV testing of provider-collected samples missed 6.1%-15.2% of CIN3+, and hrHPV testing of self-collected samples missed 3.0% of CIN3+. Conclusion: Among WWH in the Dominican Republic, HPV testing, whether provider- or self-collected, outperformed cytology for detection of CIN3+. Both 13- and 8-genotype hrHPV panels demonstrated high sensitivity but low specificity, resulting in high referral rates to colposcopy. These findings support transitioning to primary HPV-based screening for WWH in the Dominican Republic to increase accuracy in detecting precancer and reduce the cervical cancer burden among WWH.